WO2002094827A1 - Derives de tropane condenses et utilisation de ceux-ci comme inhibiteurs de recaptage de neurotransmetteur monoamine - Google Patents

Derives de tropane condenses et utilisation de ceux-ci comme inhibiteurs de recaptage de neurotransmetteur monoamine Download PDF

Info

Publication number
WO2002094827A1
WO2002094827A1 PCT/DK2002/000345 DK0200345W WO02094827A1 WO 2002094827 A1 WO2002094827 A1 WO 2002094827A1 DK 0200345 W DK0200345 W DK 0200345W WO 02094827 A1 WO02094827 A1 WO 02094827A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkynyl
aryl
alkenyl
azatricyclo
Prior art date
Application number
PCT/DK2002/000345
Other languages
English (en)
Inventor
Bjarne H. Dahl
Alex Haahr Gouliaev
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of WO2002094827A1 publication Critical patent/WO2002094827A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • This invention relates to fused tropane derivatives.
  • the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the optically active isomer of the invention.
  • WO 97/16451 describes fused tropane-derivatives and their use as mixed monoamine neu retransmitter re-uptake inhibitors.
  • the document specifically discloses a number of (1S,2S,4S,7R)-8-azatricyclo[5.4.0.0 4,8 ]undecan derivatives and (1 S,3S,4S,8R)-7-azatricyclo[5.3.0.0 4 ' 8 ]decan derivatives.
  • the invention provides a compound of general formula I,
  • the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention together with at least one pharmaceutically-acceptable carrier, excipient or diluent.
  • the invention provides a method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neu retransmitter re-uptake in the central nervous system (CNS), which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention.
  • CNS central nervous system
  • the invention provides a compound of general formula I,
  • R 3 and R 4 are independently hydrogen, halogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, or -(CH 2 ) q -COOR 2 ;
  • R 2 , R 5 and R 6 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, or arylalkyl, -CO-alkyl, or -S0 2 -alkyl;
  • R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, or arylalkyl;
  • R 9 is alkyl, alkenyl or alkynyl
  • R 1 is alkyl, alkenyl, alkynyl, aryl, or arylalkyl; where said aryl groups may be substituted one or more times with substituents selected from the group consisting of halogen, CF 3 , CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino and nitre;
  • W and W" are each independently O or S; n is 1 , 2, 3, or 4; m is 2, 3, 4, or 5; p is 1 , 2, 3, 4, or 5; and q is O, 1 , 2, 3, or 4.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides the use of a compound of the invention, or a pharmaceutically acceptable addition salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter reuptake in the central nervous system.
  • the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention.
  • the invention relates to for the preparation of the compounds of the invention comprising forming a fused ring having the formula
  • n and R 1 are defined as above, by ring-closure of a compound having the formula
  • n and R 1 is as defined above and thereafter optionally converting the compound obtained to another compound of the invention using conventional methods, and/or optionally forming a pharmaceutically acceptable salt thereof.
  • R 3 and R 4 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, or -(CH 2 ) q -COOR 2 ;
  • R 2 , R 5 and R 6 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, or arylalkyl, -CO-alkyl, or -S0 -alkyl;
  • R 7 and R 8 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, or arylalkyl;
  • R 1 is aryl; where said aryl group may be substituted one or more times with substituents selected from the group consisting of halogen, CF 3 , CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino and nitre;
  • n is 1 , 2, or 3;
  • m is 2, 3, 4, or 5;
  • p is 1 , 2, 3, 4, or 5; and
  • q is O, 1 , 2, 3, or 4.
  • the invention relates of (1 R,2R,4R,7S)-8- azatricyclo[5.4.0.0 4,8 ]undecan derivates of formula I.
  • the invention relates to (1 R,3R,4R,8S)-7-azatricyclo[5.3.0.0 4,8 ]decan derivatives of formula I.
  • the invention relates of
  • R 5 is hydrogen. In a still further embodiment, R 5 is alkyl, such as methyl or ethyl.
  • R 1 is aryl, which aryl group may be substituted one or more times with halogen.
  • R 1 is phenyl substituted once with halogen, such as chlorine.
  • R 1 is phenyl substituted twice with halogen, such as chlorine.
  • Z is hydrogen.
  • n is 1.
  • n is 2.
  • R 5 is hydrogen
  • R 1 is aryl; where said aryl group may be substituted one or more times with substituents selected from the group consisting of halogen; and n is 1 , or 2.
  • R 5 is hydrogen or alkyl.
  • R 1 is phenyl, substituted once or twice with halogen; and n is 1.
  • R 1 is phenyl substituted once or twice with chlorine.
  • R 1 is 4-chlorophenyl.
  • R 1 is 3,4-dichlorophenyl.
  • the compound of general formula I is selected from: (1 R,3R,4R,8S)-3-(3,4-Dichloropehnyl)-7-azatricyclo[5.3.0.0 4 ' 8 ]decan-5-one,
  • halogen represents a fluorine, a chlorine, a bromine or an iodine atom.
  • Alkyl means a straight chain or branched chain of one to six carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl; methyl, ethyl, propyl and isopropyl are preferred groups.
  • Cycloalkyl means cyclic alkyl of three to seven carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
  • Alkenyl means a group of from two to six carbon atoms, including at least one double bond, for example, but not limited to ethenyl, 1 ,2- or 2,3-propenyl, or 1 ,2-, 2,3-, or 3,4-butenyl.
  • Alkynyl means a group of from two to six carbon atoms, including at least one triple bond, for example, but not limited to ethynyl, 1 ,2-, 2,3-propynyl, or 1 ,2-, 2,3- or 3,4-butynyl.
  • Alkoxy is O-alkyl, wherein alkyl is as defined above.
  • Acyl is -CO-alkyl wherein alkyl is as defined above.
  • Cycloalkoxy means O-cycloalkyl, wherein cycloalkyl is as defined above. Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
  • Amino is NH or NH-alkyl or N-(alkyl) 2 , wherein alkyl is as defined above.
  • Aryl is a carbocyclic aromatic ring system such as phenyl or naphthyl (1- naphthyl or 2-naphthyl).
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention. It will be appreciated by those skilled in the art that some compounds of the present invention contain chiral centres and that such compounds exist in the form of isomers. Examples of such isomers are the 5R- and the 5S-isomers of the (1S,3S,4S,8R)-7-azatricyclo[5.3.0.0 4,8 ]decan derivatives. The invention includes all such isomers and any mixtures thereof including racemic mixtures.
  • the compounds of the invention may be prepared in numerous ways.
  • the compounds of the invention and their pharmaceutically acceptable derivatives may thus be prepared by any method known in the art for the preparation of compounds of analogous structure, and as shown in the representative examples which follow.
  • the chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
  • pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from
  • Metal salts of a chemical compound of the invention includes alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.
  • onium salts of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • the chemical substance according to the invention may be administered as such or in the form of a suitable prodrug.
  • prodrug denotes a compound, which is a drug precursor and which, following administration and absorption, release the drug in vivo via some metabolic process.
  • Particularly favoured prodrugs are those that increase the bioavailability of the compounds of the invention (e.g. by allowing an orally administrered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a specific biological compartment (e.g. the brain or lymphatic system).
  • suitable prodrugs of the substances according to the invention include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
  • the chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • Labelled Compounds The compounds of the invention may be used in their labelled or unlabelled form.
  • label stands for the binding of a marker to the compound of interest that will allow easy quantitative detection of said compound.
  • the labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo re- ceptor imaging.
  • the labelled isomer of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage.
  • the radionuclide is preferably selected from H
  • the physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon
  • MRS Magnetic Resonance Imaging
  • MRI Magnetic Resonance Imaging
  • the compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • the end product of the reaction described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • the compounds of the invention may be tested for its ability to inhibit the reuptake of the monoamine neurotransmitters in synaptosomes, eg such as described in WO 97/16451. Based on the balanced activity observed in these tests the compound of the invention is considered useful for combating diseases, disorders or conditions associated with the dopaminergic, noradrenalinergic and/or serotonergic neural system.
  • the diseases, disorders or conditions contemplated in this context are eating disorders, obesity, anorexia nervosa, disorders of sleep, panic disorders, social phobia, dementia, senile dementia, pre-senile dementia, memory deficits, memory loss, Alzheimer's disease, chronic fatigue syndrome, anxiety, pseudodementia, Ganser's syndrome, narcolepsy, drug addiction or misuse, alcoholism, tobacco abuse, panic disorder, post-traumatic syndrome, migraine, pain, attention deficit hyperactivity disorder, autism, mutism, trichotillomania, Parkinson's disease, depression, attention, alertness, arousal, vigilance, premature ejaculation, and erectile dysfunction.
  • the compounds of the invention are considered particularly useful for the treatment, prevention or alleviation of depression, pseudodementia, Ganser's syndrome, obsessive compulsive disorders, panic disorders, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety and eating disorders.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical compound of the invention.
  • a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the chemical compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefor, and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof.
  • forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations intended for conversion shortly before use to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the compositions may be provided in single or multi-dose form.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, tnchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, tnchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
  • a therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity e.g. ED 50 and LD 50
  • ED 50 and LD 50 may be determined by standard pharmacological procedures in cell cultures or experimental animals.
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD 50 /ED 50 .
  • Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 0.01 to about 500 mg of active ingredient per individual dose, preferably of from about 0.1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.01 ⁇ g/kg i.v. and 0.1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system (CNS), and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of the optically active isomer of the invention.
  • CNS central nervous system
  • the invention provides a method of combating depression, pseudodementia, Ganser's syndrome, obsessive compulsive disorders, panic disorders, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety and eating disorders.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o.
  • the upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.
  • (+)-Ecgonine ethylester (-)-2-Carbomethoxytropinone (37.4g) in methyl alcohol (1.5L) was stirred at -45°C, sodium borohydride (37g) was added in small portions, while keeping the temperature between - 45°C and - 35°C, the reaction mixture was stirred at - 45°C for 2 hours, while keeping the temperature at - 45°C hydrochloric acid (120mL) was added drop wise. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated to a volume of approximately 120mL, added water (500mL) and washed with diethyl ether (3X100mL).
  • the organic phases was evaporated to an oil.
  • the oil was dissolved in ethyl acetate (370m L), a solution of sodium ethoxide (from 7g of sodium) was added, the resulting solution was heated at reflux for 3 hours.
  • the reaction mixture was evaporated to an oil, the residue was added toluene (0.5L) and evaporated to an oil, this was repeated.
  • the product 30 g (79%) is an oil.
  • reaction mixture was heated at reflux for 4 hours and then cooled to room temperature added water (50mL) and concentrated hydrochloric acid (15mL), then heated at reflux overnight.
  • the reaction mixture was distillated until only one phase was left (water was added occasionally), the residue was added 25% ammonia (aq.), the precipitate was isolated by filtration and air dried on the filter. Yield 6.2g (58%). MP 192-194°C.
  • the precipitate was added to a hot solution of fumaric acid (1.8g) in water (200mL), the solution was heated at reflux for 10 minutes, then cooled to 5°C, a brown gum separated and was isolated by decanting of the liquid, the brown gum was added ethyl alcohol (96%) (50mL) and water (20mL), the mixture was heated at reflux for 10 minutes and cooled to 5°C, a solid crystallized out, and was isolated by filtration. The precipitate was washed with cold (5°C) ethyl alcohol (2mL) and air dried on the filter. Yield 2.5 g (34%) MP 255- 257°C.
  • the isomer is produced as follows: To a -10°C stirred solution of triphenylphosphine (4.71 g; 18 mmol) in THF (125mL), a solution of diethylazodicarboxylate (2.82 ml) in THF (25 mL) is added drop-wise, during which reaction the temperature is kept at - 10°C by external cooling.
  • This intermediate is purified by SiO 2 column purification in EtAc:MeOH:acetone (4:1 :1), and subsequently treated with EtOH/4N NaOH for 3 hours at room-temperature. Addition of water to the reaction mixture gives a precipitate of (1 R,3R,4R,5S,8S)-3-(3,4-Dichlorophenyl)-7-azatricyclo-[5.3.0.0 4,8 ]- decan-5-ol, which is recrystallised from EtOH to give a crystalline product.
  • reaction mixture was added water and extracted 3 times with diethyl ether, the collected ether phases was washed with water and dried, then evaporated to an oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de tropane condensés. D'autres aspects de cette invention concernent l'utilisation de ces composés dans une technique thérapeutique et dans des compositions pharmaceutiques comprenant l'isomère optiquement actif de l'invention. Cette invention concerne aussi un composé représenté par la formule générale (I).
PCT/DK2002/000345 2001-05-23 2002-05-23 Derives de tropane condenses et utilisation de ceux-ci comme inhibiteurs de recaptage de neurotransmetteur monoamine WO2002094827A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100837 2001-05-23
DKPA200100837 2001-05-23

Publications (1)

Publication Number Publication Date
WO2002094827A1 true WO2002094827A1 (fr) 2002-11-28

Family

ID=8160529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000345 WO2002094827A1 (fr) 2001-05-23 2002-05-23 Derives de tropane condenses et utilisation de ceux-ci comme inhibiteurs de recaptage de neurotransmetteur monoamine

Country Status (1)

Country Link
WO (1) WO2002094827A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101453A1 (fr) * 2002-05-30 2003-12-11 Neurosearch A/S Triple inhibiteurs de recaptage de momoamine pour le traitement de douleur chronique

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016451A1 (fr) * 1995-11-02 1997-05-09 Neurosearch A/S Derives tropane condenses en tant qu'inhibiteurs de recaptage des neurotransmetteurs
WO1999061023A1 (fr) * 1998-05-22 1999-12-02 Research Triangle Institute Ligands se fixant sur les recepteurs de ***e
WO2000011001A1 (fr) * 1998-08-18 2000-03-02 Ucb, S.A. Agonistes et antagonistes muscariniques
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
WO2001023385A2 (fr) * 1999-09-27 2001-04-05 Georgetown University Nouveaux analogues de tropane

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329520B1 (en) * 1990-08-09 2001-12-11 Research Triangle Institute Cocaine receptor binding ligands
WO1997016451A1 (fr) * 1995-11-02 1997-05-09 Neurosearch A/S Derives tropane condenses en tant qu'inhibiteurs de recaptage des neurotransmetteurs
WO1999061023A1 (fr) * 1998-05-22 1999-12-02 Research Triangle Institute Ligands se fixant sur les recepteurs de ***e
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
WO2000011001A1 (fr) * 1998-08-18 2000-03-02 Ucb, S.A. Agonistes et antagonistes muscariniques
US6323194B1 (en) * 1998-08-18 2001-11-27 Ucb, S.A. Muscarinic agonists and antagonists
WO2001023385A2 (fr) * 1999-09-27 2001-04-05 Georgetown University Nouveaux analogues de tropane

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARROLL F I ET AL: "3-Aryl-2-(3'-substituted-1',2',4'-oxadiazol-5'-yl)tropane analogs of ***e: affinities at the ***e binding site at the dopamine, serotonin, and norepinephrine transporters", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 36, no. 20, April 1993 (1993-04-01), pages 2886 - 2890, XP002116829, ISSN: 0022-2623 *
DAMAJ M I ET AL: "Pharmacological characterization of nicotine's interaction with ***e and ***e analogs.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 289, no. 3, 1999, pages 1229 - 1236, XP002902604 *
TAMIZ A P A P ET AL: "Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of ***e", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 3, February 2000 (2000-02-01), pages 297 - 300, XP004188839, ISSN: 0960-894X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101453A1 (fr) * 2002-05-30 2003-12-11 Neurosearch A/S Triple inhibiteurs de recaptage de momoamine pour le traitement de douleur chronique
US7459464B2 (en) 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain

Similar Documents

Publication Publication Date Title
EP2032574B1 (fr) Nouveaux dérivés de 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyle et leur utilisation médicale
EP2029595B1 (fr) Nouveau dérivé de 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyle et son utilisation médicale
EP1397365B1 (fr) Heteroaryl-diazabicyclo-alcanes a titre de modulateurs du snc
WO2002102801A1 (fr) Derives du tropane et utilisation de ces derniers comme inhibiteurs de recaptage du neurotransmetteur monoamine
US20100286128A1 (en) 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine-receptor ligands
AU2008322957A1 (en) Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
WO2004072075A1 (fr) Nouveaux derives de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
JP2010536726A (ja) ニコチン性アセチルコリン受容体リガンドとして有用な新規１，４−ジアザ−ビシクロ〔３．２．２〕ノニルヘテロアリール誘導体
EP1984366B1 (fr) Dérivés de 3, 9-diazabicyclo ý3.3. 1¨nonane et leur utilisation en tant qu'inhibiteurs de réabsorption de neurotransmetteur de monoamine
WO2002094827A1 (fr) Derives de tropane condenses et utilisation de ceux-ci comme inhibiteurs de recaptage de neurotransmetteur monoamine
JP2011503146A (ja) 新規な１，４−ジアザ−ビシクロ［３．２．２］ノニルピリミジン誘導体及びこれらの医療上の使用
US20110257161A1 (en) Novel diaza-bicyclononyl-phenyl derivatives and their medical use
US20110112119A1 (en) Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators
US20090137625A1 (en) Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
US20040235906A1 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-up-take inhibitors
WO2002002559A1 (fr) Isomeres steriques de derives de tropane condenses et leur utilisation comme inhibiteurs du recaptage du recepteur des neurotransmetteurs de la monoamine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP